A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
30–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject with a diagnosis of definite idiopathic Parkinson's disease (PD) that is levodopa-responsive according to the United Kingdom Parkinson's Disease Society Brain Bank Criteria.
Subject must be taking an optimized and stable regimen of oral medications for PD, which has remained stable and unchanged for at least 30 days before enrollment in this study.
Subject is judged inadequately controlled on current therapy in the opinion of the Investigator and must experience a minimum of 2.5 hours of "off" time per day prior to Enrollment.
Subjects with a MMSE score greater than or equal to 24 and considered by the Investigator to not have dementia.
You may not be if
Subjects with clinically significant electrocardiogram (ECG) values.
History of significant skin conditions or disorders that in the Investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments.
Receipt of an investigational product within at least 6 weeks prior to study drug administration.
Subjects with moderate to severe kidney disease.
Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951.
Patient/caregiver that cannot demonstrate proper use of the devices (drug pump and wearable device) will not be allowed to participate.